Related Experiment Video
Updated: Jun 8, 2026

Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
Older donors and older recipients in kidney transplantation
Giovanni Stallone1, Barbara Infante, Loreto Gesualdo
1Department of Biomedical Sciences, University of Foggia, Italy. g.stallone@unifg.it
Abstract:
Over the last 2 decades, while kidney transplantation became the therapy of choice for end-stage renal disease, the increasing gap between the limited supply of cadaveric donors and the rising demand for kidneys led to the consideration of alternative strategies to provide more organs for transplant. The significant increase of mean donor age suggested the use of kidneys from older donors. In addition, an increasing number of donors with significant comorbidities (e.g., hypertension and diabetes) or deceased due to stroke have been used since the early 1990s, leading to the definition of the fuzzy and disputed concept of "marginal" donors. Such organs are eligible for organ donation but, because of extreme age and other clinical characteristics, are expected to produce allografts at risk for diminished posttransplant function. Thus, the challenge is now to improve the graft outcome gap between patients receiving grafts from "marginal" and "optimal" donors. This implies appropriate transplantation strategies during all transplant phases, including reduction of cold ischemia time, recipient selection, adaptation of immunosuppressive drug regimens, increase in nephron mass by dual kidney transplantation and improvement in the graft selection process using histological criteria. This review summarizes the current definition of a marginal donor and provides some suggestions for clinical management of these particular kidney transplants. We believe that in this particular transplanted population, an effective balance should be ensured between maintaining graft survival, reducing the impact of immunosuppressive toxicity and maximizing patient quality of life through the reduced incidence of cardiovascular disease and malignancies.
Insights
Kidney transplantation faces a donor shortage, leading to the use of "marginal" organs from older or comorbid donors. Strategies are needed to optimize outcomes for these kidney transplants.
Area of Science:
- Nephrology
- Transplantation immunology
- Organ donation
Background:
- Kidney transplantation is the preferred treatment for end-stage renal disease.
- A growing gap exists between kidney donor supply and demand.
- Increased use of organs from older donors and those with comorbidities has led to the concept of "marginal" donors.
Purpose of the Study:
- To review the definition of marginal kidney donors.
- To suggest clinical management strategies for kidney transplants using marginal organs.
- To address the challenge of improving graft outcomes from marginal donors compared to optimal donors.
Main Methods:
- Review of current literature on marginal kidney donors.
- Analysis of strategies to improve outcomes in kidney transplantation.
- Discussion of clinical management including cold ischemia time, recipient selection, immunosuppression, dual kidney transplantation, and histological graft selection.
Main Results:
- Marginal donor organs, while eligible, carry a risk of diminished post-transplant function.
- Strategies to improve outcomes include reducing cold ischemia time, careful recipient selection, tailored immunosuppression, and increasing nephron mass.
- Histological criteria are important for graft selection.
Conclusions:
- Effective management of marginal kidney transplants requires balancing graft survival, immunosuppressive toxicity, and patient quality of life.
- Reducing cardiovascular disease and malignancy incidence is crucial for long-term patient well-being.
- Optimizing transplantation strategies for marginal organs is essential to bridge the gap with optimal donor transplants.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
